TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Women veterans gather for conference A day-long conference in Albuquerque Sept. 12 will address issues that women military veterans face. feeds.bizjournals.com |
Arena’s Lorcaserin Has Safety Edge Zacks.com submits: Results from Arena’s (ARNA) phase III BLOSSOM study are strikingly similar to the BLOOM study, with mean total weight loss for the 10mg lorcaserin BID group coming in at 17.0 lbs in BLOSSOM vs. 17.9 lbs in BLOOM. These equated to 7.9% and 8.2% mean absolute weight loss. The placebo was 3.9% and 3.4% in each trial, respectively, putting the mean placebo-adjusted weight loss for each trial at 4.0% and 4.8%. Total categorical weight loss for the completer analysis was 63.2% in BLOSSOM and 66.4% in BLOOM, vs. 34.9% and 32.1% for the placebo. Per the FDA draft guidance: “A product can be considered effective for weight management if after one year of treatment either of the following occurs: (1) the difference in mean weight loss between the active-product and placebo-treated groups is at least 5% and the difference is statistically significant, or (2) the proportion of subjects who lose greater than or equal to 5% of baseline body weight in the active-product group is at least 35%, is approximately double the proportion in the placebo-treated group, and the difference between groups is statistically significant.Complete Story » seekingalpha.com |
Are Metals Good for You? The medicinal properties of metals have been touted for millennia. But such claims have always been one part medicine to one million parts marketing. online.wsj.com |
GeneLink Reports Third Quarter Results (Business Wire) ORLANDO, Fla.----GeneLink, Inc. , a leading consumer genomics biotech company, today reported financial results for the fiscal 2009 three-month period ended September 30, 2009. us.rd.yahoo.com |
Closing Human Genome Sciences Trader Mark submits:I really tried to be more of a traditional mutual fund manager the past 2 weeks, and not trade as much - let the winners run (yada yada yada). Thus far, for many positions I have sat on my hands with, all I've been rewarded with by not locking in gains are stocks that have completely retraced their moves up, and all my unrealized gains in those stocks have been vanquished. Human Genome Sciences (HGSI) is similar to Myriad Genetics (MYGN) in that I had a nice gain - although in this case much larger than MYGN; and that is now all gone. Just as with Myriad, HGSI broke out nicely in a very short period of time as we entered the stock giving us a textbook move - but it has now given it all back in just under a week. I am going to take the 3% loss and leave this position in the $29.40s as I see a gap under $28.50 which is yearning to be filled.Now I remember why I don't act like a traditional "buy and hold" fund manager - it stinks unless the market is going straight up. Back to 1000% annual turnover I suppose!Complete Story » seekingalpha.com |